Navigation Links
Dragon to Present at BioContact Quebec 2008
Date:9/25/2008

VANCOUVER, Sept. 25 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: DRUG; BBSE: DRP), a leading international pharmaceutical company, today announced that Ms. Maggie Deng, Chief Operating Officer and Mr. Garry Wong, Chief Financial Officer will present at 9:30 a.m. ET on Friday, October 3, 2008 at BioContact Quebec 2008 at the Chateau Frontenac hotel in Quebec City, Canada.

Ms. Maggie Deng and Mr. Garry Wong will present Dragon Pharma's business overview including product lines, competitive strengths, and key growth strategies.

BioContact Quebec 2008 is a biopharmaceutical partnership symposium that brings together over 1,200 participants from biopharmaceutical companies to present various sectors and disciplines of their companies. The conference will be held on October 1-3, for more information about the conference, please visit http://www.biocontact.qc.ca/english/default.html.

About Dragon Pharmaceutical Inc.

Dragon Pharmaceutical, headquartered in Vancouver, Canada, is a leading manufacturer and distributor of a broad line of high-quality antibiotic products including 7-ACA, a key intermediate to produce cephalosporin antibiotics, clavulanic acid, and formulated cephalosporin antibiotic drugs. Dragon is the third largest 7-ACA producer and the first manufacturer and market leader of clavulanic acid products in China. Dragon utilizes its nationwide sales distribution network, close customer relationships, understanding of local markets and customer needs and low cost structure to outperform its international and domestic peers. With an annual capacity of 780 tons, Dragon is the largest exporter of 7-ACA in China. To learn more about Dragon Pharmaceutical Inc., please visit http://www.dragonpharma.com.


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dragon Pharma Announces Results of the Annual General Meeting
2. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
3. 3SBio Inc. to Present at The Oppenheimer 2nd Annual China Dragon Call Conference
4. Dragon Pharma announces 2007 full year financial results
5. Dragon retains leading investor relations firm
6. Dragon announces new product launch; increase in annual production output capacity
7. Dragon Announces R&D Achievement in Biotech Manufacturing Process
8. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
11. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... ACEA Biosciences, a pioneer in cell analysis instrumentation and the development of ... as the new Vice President of Global Clinical Development. With more than 15 ... will now team with Dr. Li Xu, Chief Medical Officer, and Dr. Xiao Xu, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... science and biotechnology companies today announced it named Joan Siefert Rose as ... out of Durham, NC and will begin work immediately. , Rose most recently ...
(Date:2/28/2017)... , Feb. 28, 2017 Sangamo ... genome editing, today reported its fourth quarter and ... "Early this year we rebranded our ... clinical development of genomic therapies using our industry ... gene regulation and cell therapy," said Sandy ...
(Date:2/27/2017)... 2017 A Europe-wide survey of institutes conducted ... animals in their research treat them with due care. The survey ... analysis of the results indicates that there is a strong commitment ... into practice the principles of the 3Rs (Refine, Reduce, Replace)  ... What are the ...
Breaking Biology Technology:
(Date:2/3/2017)... A new independent identity strategy consultancy firm ... . Designed to fill a critical niche in technical ... partners Mark Crego and Janice Kephart ... identity expertise that span federal governments, the 9/11 Commission, ... combined expertise has a common theme born from a ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/24/2017)... Jan. 24, 2017 Biopharm Reports has ... laboratory use of nuclear magnetic resonance spectroscopy (NMR). ... and profiled current practices, developments, trends and end-user ... as growth and opportunities. These areas include growth ... instruments, needs and innovation requirements, hyphenated NMR techniques, ...
Breaking Biology News(10 mins):